Young Jane M, O'brien Christopher, Harrison James D, Solomon Michael J
Surgical Outcomes Research Centre, Sydney South West Area Health Service and the University of Sydney, PO Box M157, Missenden Rd NSW 2050, Sydney, Australia.
Head Neck. 2006 Mar;28(3):235-43. doi: 10.1002/hed.20315.
This study investigated the individual and collective ("community") equipoise of surgeons and oncologists and their willingness to take part in each of six hypothetical randomized controlled trials in head and neck oncology.
A survey was mailed to Australasian head and neck specialists.
Among 109 respondents (74% response), the scenario with the highest level of individual equipoise pertained to the use of adjuvant interferon for patients with high-risk malignant melanoma, with 45% indicating complete uncertainty between treatment approaches. Significant differences in levels of community equipoise were demonstrated between surgeons and oncologists for three of the scenarios. Willingness to participate in randomized controlled trials ranged from 39% to 72%. Increasing strength of treatment preference was associated with unwillingness to participate in randomized controlled trials for two of six scenarios.
High levels of equipoise and willingness to participate in clinical research augur well for future randomized controlled trials in head and neck oncology.
本研究调查了外科医生和肿瘤学家的个体和集体（“群体”） equipoise 以及他们参与六项头颈肿瘤学假设随机对照试验中每一项的意愿。
向澳大利亚和新西兰的头颈专科医生邮寄了一份调查问卷。
在109名受访者中（回复率为74%），个体 equipoise 水平最高的情况涉及高危恶性黑色素瘤患者使用辅助干扰素，45% 的人表示在治疗方法之间完全不确定。在三种情况下，外科医生和肿瘤学家之间群体 equipoise 水平存在显著差异。参与随机对照试验的意愿从39% 到72% 不等。在六种情况中的两种情况下，治疗偏好强度的增加与参与随机对照试验的意愿降低相关。
高水平的 equipoise 和参与临床研究的意愿对头颈肿瘤学未来的随机对照试验是个好兆头。
